CDKL5 Gene-Related Encephalopathy: Pathophysiology, Clinical Presentation, Developmental Prognosis, and Treatment

Yoko Takahashi; Parikh Sumit; Elia M. Pestana Knight

doi:10.1055/s-0038-1641161

Journal of Pediatric Epilepsy, Inhaltsverzeichnis

Journal of Pediatric Epilepsy 2018; 07(01): 001-007
DOI: 10.1055/s-0038-1641161

Review Article

Georg Thieme Verlag KG Stuttgart · New York

CDKL5 Gene-Related Encephalopathy: Pathophysiology, Clinical Presentation, Developmental Prognosis, and Treatment

Yoko Takahashi

¹Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States

²Department of Epileptology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan

³Postgraduate Education Center, Kameda Medical Center, Kamogawa, Chiba, Japan

,

Parikh Sumit

⁴Department of Neurogenetics, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States

,

Elia M. Pestana Knight

¹Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, United States

› Institutsangaben

Abstract

The cyclin-dependent kinase-like 5 gene (CDKL5) plays a crucial role in brain development. Diseases related to mutations in the CDKL5 gene are considered relatively new disorders. Patients with CDKL5-related disease usually present with early-onset refractory epilepsy and severe global developmental delay. Epilepsy is severe and poorly responsive to conventional medical treatment in most of these patients. Other neurological problems include movement disorder, autonomic symptoms, and sleep problems. In addition to neurological problems, patients may have orthopedic and gastrointestinal disease. Arrhythmia and other heart diseases are uncommon, though more information is needed. Management of patients affected with these diseases requires a multidisciplinary team. Seizures in CDKL5-related disease are very refractory, and treatment with antiseizure medications often fails. Some new drugs currently in clinical trials may show benefit. This article reviews the current status of CDKL5 research, highlighting the pathophysiology, clinical presentation, developmental prognosis, and treatment of CDKL5-related diseases, with the goal of increasing disease recognition.

Keywords

CDKL5 gene - epileptic encephalopathy - refractory epilepsy

Volltext

Referenzen

References
1 Kalscheuer VM, Tao J, Donnelly A. , et al. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet 2003; 72 (06) 1401-1411
2 Tao J, Van Esch H, Hagedorn-Greiwe M. , et al. Mutations in the X-linked cyclin-dependent kinase-like 5 (CDKL5/STK9) gene are associated with severe neurodevelopmental retardation. Am J Hum Genet 2004; 75 (06) 1149-1154
3 Weaving LS, Christodoulou J, Williamson SL. , et al. Mutations of CDKL5 cause a severe neurodevelopmental disorder with infantile spasms and mental retardation. Am J Hum Genet 2004; 75 (06) 1079-1093
4 Mari F, Azimonti S, Bertani I. , et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet 2005; 14 (14) 1935-1946
5 Scala E, Ariani F, Mari F. , et al. CDKL5/STK9 is mutated in Rett syndrome variant with infantile spasms. J Med Genet 2005; 42 (02) 103-107
6 Fehr S, Wilson M, Downs J. , et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet 2013; 21 (03) 266-273
7 Mercimek-Mahmutoglu S, Patel J, Cordeiro D. , et al. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia 2015; 56 (05) 707-716
8 Rim JH, Kim SH, Hwang IS. , et al. Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing. BMC Med Genomics 2018; 11 (01) 6
9 Mei D, Marini C, Novara F. , et al. Xp22.3 genomic deletions involving the CDKL5 gene in girls with early onset epileptic encephalopathy. Epilepsia 2010; 51 (04) 647-654
10 Archer HL, Evans J, Edwards S. , et al. CDKL5 mutations cause infantile spasms, early onset seizures, and severe mental retardation in female patients. J Med Genet 2006; 43 (09) 729-734
11 Bahi-Buisson N, Nectoux J, Rosas-Vargas H. , et al. Key clinical features to identify girls with CDKL5 mutations. Brain 2008; 131 (Pt 10): 2647-2661
12 Elia M, Falco M, Ferri R. , et al. CDKL5 mutations in boys with severe encephalopathy and early-onset intractable epilepsy. Neurology 2008; 71 (13) 997-999
13 Artuso R, Mencarelli MA, Polli R. , et al. Early-onset seizure variant of Rett syndrome: definition of the clinical diagnostic criteria. Brain Dev 2010; 32 (01) 17-24
14 Mangatt M, Wong K, Anderson B. , et al. Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome. Orphanet J Rare Dis 2016; 11: 39
15 Fehr S, Leonard H, Ho G. , et al. There is variability in the attainment of developmental milestones in the CDKL5 disorder. J Neurodev Disord 2015; 7 (01) 2
16 Montini E, Andolfi G, Caruso A. , et al. Identification and characterization of a novel serine-threonine kinase gene from the Xp22 region. Genomics 1998; 51 (03) 427-433
17 Kilstrup-Nielsen C, Rusconi L, La Montanara P. , et al. What we know and would like to know about CDKL5 and its involvement in epileptic encephalopathy. Neural Plast 2012; 2012: 728267
18 Williamson SL, Giudici L, Kilstrup-Nielsen C. , et al. A novel transcript of cyclin-dependent kinase-like 5 (CDKL5) has an alternative C-terminus and is the predominant transcript in brain. Hum Genet 2012; 131 (02) 187-200
19 Fichou Y, Nectoux J, Bahi-Buisson N, Chelly J, Bienvenu T. An isoform of the severe encephalopathy-related CDKL5 gene, including a novel exon with extremely high sequence conservation, is specifically expressed in brain. J Hum Genet 2011; 56 (01) 52-57
20 Lin C, Franco B, Rosner MR. CDKL5/Stk9 kinase inactivation is associated with neuronal developmental disorders. Hum Mol Genet 2005; 14 (24) 3775-3786
21 Rusconi L, Salvatoni L, Giudici L. , et al. CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. J Biol Chem 2008; 283 (44) 30101-30111
22 Ricciardi S, Kilstrup-Nielsen C, Bienvenu T, Jacquette A, Landsberger N, Broccoli V. CDKL5 influences RNA splicing activity by its association to the nuclear speckle molecular machinery. Hum Mol Genet 2009; 18 (23) 4590-4602
23 Chen Q, Zhu YC, Yu J. , et al. CDKL5, a protein associated with Rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. J Neurosci 2010; 30 (38) 12777-12786
24 Ricciardi S, Ungaro F, Hambrock M. , et al. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat Cell Biol 2012; 14 (09) 911-923
25 Nawaz MS, Giarda E, Bedogni F. , et al. CDKL5 and Shootin1 interact and concur in regulating neuronal polarization. PLoS One 2016; 11 (02) e0148634
26 Fuchs C, Trazzi S, Torricella R. , et al. Loss of CDKL5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3β signaling. Neurobiol Dis 2014; 70: 53-68
27 Amendola E, Zhan Y, Mattucci C. , et al. Mapping pathological phenotypes in a mouse model of CDKL5 disorder. PLoS One 2014; 9 (05) e91613
28 Kaufmann WE, Moser HW. Dendritic anomalies in disorders associated with mental retardation. Cereb Cortex 2000; 10 (10) 981-991
29 Neuhofer D, Henstridge CM, Dudok B. , et al. Functional and structural deficits at accumbens synapses in a mouse model of Fragile X. Front Cell Neurosci 2015; 9: 100
30 La Montanara P, Rusconi L, Locarno A. , et al. Synaptic synthesis, dephosphorylation, and degradation: a novel paradigm for an activity-dependent neuronal control of CDKL5. J Biol Chem 2015; 290 (07) 4512-4527
31 Valli E, Trazzi S, Fuchs C. , et al. CDKL5, a novel MYCN-repressed gene, blocks cell cycle and promotes differentiation of neuronal cells. Biochim Biophys Acta 2012; 1819 (11–12): 1173-1185
32 Nardou R, Ferrari DC, Ben-Ari Y. Mechanisms and effects of seizures in the immature brain. Semin Fetal Neonatal Med 2013; 18 (04) 175-184
33 Moseley BD, Dhamija R, Wirrell EC, Nickels KC. Historic, clinical, and prognostic features of epileptic encephalopathies caused by CDKL5 mutations. Pediatr Neurol 2012; 46 (02) 101-105
34 Guerrini R, Parrini E. Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies. Epilepsia 2012; 53 (12) 2067-2078
35 Melani F, Mei D, Pisano T. , et al. CDKL5 gene-related epileptic encephalopathy: electroclinical findings in the first year of life. Dev Med Child Neurol 2011; 53 (04) 354-360
36 Bahi-Buisson N, Kaminska A, Boddaert N. , et al. The three stages of epilepsy in patients with CDKL5 mutations. Epilepsia 2008; 49 (06) 1027-1037
37 Stalpers XL, Spruijt L, Yntema HG, Verrips A. Clinical phenotype of 5 females with a CDKL5 mutation. J Child Neurol 2012; 27 (01) 90-93
38 Saletti V, Canafoglia L, Cambiaso P, Russo S, Marchi M, Riva D. A CDKL5 mutated child with precocious puberty. Am J Med Genet A 2009; 149A (05) 1046-1051
39 Bahi-Buisson N, Girard B, Gautier A. , et al. Epileptic encephalopathy in a girl with an interstitial deletion of Xp22 comprising promoter and exon 1 of the CDKL5 gene. Am J Med Genet B Neuropsychiatr Genet 2010; 153B (01) 202-207
40 Grosso S, Brogna A, Bazzotti S, Renieri A, Morgese G, Balestri P. Seizures and electroencephalographic findings in CDKL5 mutations: case report and review. Brain Dev 2007; 29 (04) 239-242
41 Liang JS, Shimojima K, Takayama R. , et al. CDKL5 alterations lead to early epileptic encephalopathy in both genders. Epilepsia 2011; 52 (10) 1835-1842
42 Szafranski P, Golla S, Jin W. , et al. Neurodevelopmental and neurobehavioral characteristics in males and females with CDKL5 duplications. Eur J Hum Genet 2015; 23 (07) 915-921
43 Kobayashi Y, Tohyama J, Kato M. , et al. High prevalence of genetic alterations in early-onset epileptic encephalopathies associated with infantile movement disorders. Brain Dev 2016; 38 (03) 285-292
44 Hagebeuk EE, van den Bossche RA, de Weerd AW. Respiratory and sleep disorders in female children with atypical Rett syndrome caused by mutations in the CDKL5 gene. Dev Med Child Neurol 2013; 55 (05) 480-484
45 Pini G, Bigoni S, Engerström IW. , et al; ESRRA group. Variant of Rett syndrome and CDKL5 gene: clinical and autonomic description of 10 cases. Neuropediatrics 2012; 43 (01) 37-43
46 Van Esch H, Jansen A, Bauters M, Froyen G, Fryns JP. Encephalopathy and bilateral cataract in a boy with an interstitial deletion of Xp22 comprising the CDKL5 and NHS genes. Am J Med Genet A 2007; 143 (04) 364-369
47 Leoncini S, De Felice C, Signorini C. , et al. Cytokine dysregulation in MECP2- and CDKL5-related Rett syndrome: relationships with aberrant redox homeostasis, inflammation, and ω-3 PUFAs. Oxid Med Cell Longev 2015; 2015: 421624 doi: 10.1155/2015/421624
48 Cortelazzo A, de Felice C, Leoncini S. , et al. Inflammatory protein response in CDKL5-Rett syndrome: evidence of a subclinical smouldering inflammation. Inflamm Res 2017; 66 (03) 269-280
49 Müller A, Helbig I, Jansen C. , et al. Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. Eur J Paediatr Neurol 2016; 20 (01) 147-151
50 Krajnc N, Župančič N, Oražem J. Epilepsy treatment in Rett syndrome. J Child Neurol 2011; 26 (11) 1429-1433
51 Vigevano F, Arzimanoglou A, Plouin P, Specchio N. Therapeutic approach to epileptic encephalopathies. Epilepsia 2013; 54 (Suppl. 08) 45-50
52 Yawno T, Miller SL, Bennet L. , et al. Ganaxolone: a new treatment for neonatal seizures. Front Cell Neurosci 2017; 11: 246
53 Ligsay A, Van Dijck A, Nguyen DV. , et al. A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome. J Neurodev Disord 2017; 9 (01) 26
54 Baba S, Sugawara Y, Moriyama K. , et al. Amelioration of intractable epilepsy by adjunct vagus nerve stimulation therapy in a girl with a CDKL5 mutation. Brain Dev 2017; 39 (04) 341-344